Atara Historical Income Statement
| ATRA Stock | USD 8.59 0.13 1.49% |
Historical analysis of Atara Biotherapeutics income statement accounts such as Selling General Administrative of 47.3 M, Other Operating Expenses of 196.3 M or Research Development of 148.2 M can show how well Atara Biotherapeutics performed in making a profits. Evaluating Atara Biotherapeutics income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Atara Biotherapeutics's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Atara Biotherapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Atara Biotherapeutics is a good buy for the upcoming year.
Atara |
About Atara Income Statement Analysis
Atara Biotherapeutics Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Atara Biotherapeutics shareholders. The income statement also shows Atara investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Atara Biotherapeutics Income Statement Chart
Add Fundamental
Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Atara Biotherapeutics. It is also known as Atara Biotherapeutics overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Total Operating Expenses
The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.Gross Profit
Gross profit is a required income statement account that reflects total revenue of Atara Biotherapeutics minus its cost of goods sold. It is profit before Atara Biotherapeutics operating expenses, interest payments and taxes. Gross profit is also known as gross margin. The profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services.Most accounts from Atara Biotherapeutics' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Atara Biotherapeutics current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Atara Biotherapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade Atara Stock refer to our How to Trade Atara Stock guide.At present, Atara Biotherapeutics' Income Tax Expense is projected to decrease significantly based on the last few years of reporting. The current year's Total Revenue is expected to grow to about 10.6 M, whereas Depreciation And Amortization is forecasted to decline to about 4.8 M.
| 2022 | 2023 | 2024 | 2025 (projected) | Net Interest Income | 2.0M | 944K | 849.6K | 807.1K | Interest Income | 2.0M | 4.8M | 5.5M | 3.2M |
Atara Biotherapeutics income statement Correlations
Click cells to compare fundamentals
Atara Biotherapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Atara Biotherapeutics income statement Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Depreciation And Amortization | 8.3M | 9.3M | 14.6M | 4.8M | 5.6M | 4.8M | |
| Selling General Administrative | 64.4M | 78.8M | 71.6M | 50.9M | 58.5M | 47.3M | |
| Other Operating Expenses | 309.1M | 360.8M | 344.1M | 284.6M | 327.3M | 196.3M | |
| Operating Income | (309.1M) | (340.5M) | (280.5M) | (276.0M) | (248.4M) | (260.8M) | |
| Ebit | (309.1M) | (340.5M) | (228.3M) | (270.8M) | (243.7M) | (255.9M) | |
| Research Development | 244.7M | 282.0M | 272.5M | 224.8M | 258.5M | 148.2M | |
| Ebitda | (300.7M) | (331.1M) | (213.7M) | (266.0M) | (239.4M) | (251.4M) | |
| Total Operating Expenses | 309.1M | 360.8M | 344.1M | 275.7M | 317.0M | 195.5M | |
| Income Before Tax | (306.6M) | (340.1M) | (228.3M) | (276.1M) | (248.5M) | (260.9M) | |
| Total Other Income Expense Net | 2.4M | 367K | 52.2M | (105K) | (120.8K) | (114.7K) | |
| Net Income | (306.6M) | (340.1M) | (2.3B) | (276.1M) | (248.5M) | (260.9M) | |
| Income Tax Expense | (44K) | 12K | 15K | 46K | 13.5K | 15.9K | |
| Interest Expense | 10.8M | 9.7M | 2.0M | 5.3M | 6.1M | 4.0M | |
| Total Revenue | 3.6M | 20.3M | 63.6M | 8.6M | 9.9M | 10.6M | |
| Gross Profit | (9.9M) | 20.3M | 49.0M | (313K) | (360.0K) | (342.0K) | |
| Net Income From Continuing Ops | (306.6M) | (340.1M) | (228.3M) | (290.2M) | (261.2M) | (274.3M) | |
| Cost Of Revenue | 9.9M | 11.4M | 14.6M | 8.9M | 10.2M | 6.4M | |
| Non Operating Income Net Other | 4.7M | 2.4M | 367K | 52.2M | 60.1M | 63.1M | |
| Net Income Applicable To Common Shares | (291.0M) | (306.6M) | (340.1M) | (228.3M) | (205.5M) | (215.7M) | |
| Tax Provision | 12K | 15K | 46K | 6K | 6.9K | 4.2K | |
| Interest Income | 2.4M | 367K | 2.0M | 4.8M | 5.5M | 3.2M | |
| Net Interest Income | 2.4M | 367K | 2.0M | 944K | 849.6K | 807.1K | |
| Reconciled Depreciation | 8.3M | 9.3M | 5.7M | 4.9M | 5.6M | 6.3M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Atara Biotherapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Atara Biotherapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Atara Biotherapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Atara Biotherapeutics Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Atara Biotherapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade Atara Stock refer to our How to Trade Atara Stock guide.You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Atara Biotherapeutics. If investors know Atara will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Atara Biotherapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (25.32) | Revenue Per Share | Quarterly Revenue Growth 17.798 | Return On Assets | Return On Equity |
The market value of Atara Biotherapeutics is measured differently than its book value, which is the value of Atara that is recorded on the company's balance sheet. Investors also form their own opinion of Atara Biotherapeutics' value that differs from its market value or its book value, called intrinsic value, which is Atara Biotherapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Atara Biotherapeutics' market value can be influenced by many factors that don't directly affect Atara Biotherapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Atara Biotherapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Atara Biotherapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Atara Biotherapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.